NASS’s 2024 Research Funding Program announced grants and traveling fellowships winners totaling $159,059 this year.
CCH demonstrated significant efficacy in reducing ventral curvature in Peyronie's disease, with a 45.4% average reduction in curvature among 32 patients. The study found that 68.8% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback